What should you know about MEK inhibitor drugs?

MEK inhibitors act on signalling proteins in the MAPK pathway, which can be overactive in melanoma with particular molecular changes. Testing of tumour tissue may help the oncology team decide whether this approach is relevant. A MEK inhibitor may be prescribed alone or paired with another targeted medicine, depending on the tumour profile and treatment plan. It is not the same as Immunotherapy, and surgery may still be needed for a primary lesion or selected spread. The aim, schedule, and monitoring plan depend on your individual cancer.

Take the medicine exactly as prescribed and do not change or stop it without contacting the oncology team. Tell them about every medicine, supplement, eye problem, heart condition, liver problem, and pregnancy possibility. Monitoring may include examinations, blood tests, heart assessment, and eye review. Keep a record of new rash, diarrhoea, swelling, fatigue, fever, vision change, or reduced exercise tolerance. Protect irritated skin from sun and use the skin-care measures recommended by your team. Keep scheduled scans and appointments even when you feel well.

Contact your oncology team promptly for severe or persistent diarrhoea, a widespread or blistering rash, painful mouth sores, unusual bleeding, yellowing skin, marked weakness, or reduced urine. Seek urgent help for chest pain, fainting, severe breathlessness, sudden vision loss, confusion, or a severe allergic reaction. Early reporting lets the team check for a medicine reaction and decide whether treatment or supportive care needs adjustment.

Ask whether molecular testing supports a MEK inhibitor, whether another medicine will be combined with it, which checks are required, which symptoms need same-day contact, and how missed doses or planned procedures should be handled.